Oxaliplatin and Topotecan in Advance Ovarian Cancer

Inclusion Criteria: * Histologically or cytologically confirmed ovarian epithelial, primary peritoneal, or fallopian tube cancer * Meets 1 of the following criteria for response to prior platinum-based therapy: * Platinum-resistant disease, defined as a disease-free interval of \< 6 months after prior platinum-based therapy OR progressive disease on a platinum-containing regimen * Platinum-sensitive disease, defined as a disease-free interval of \> 6 months after prior platinum-based therapy * Measurable or evaluable disease: Measurable disease is characterized as lesions reproducibly measurable in 1 dimension; evaluable disease is defined as known disease with CA125 levels \> 50 U/mL on 2 occasions \>= 1 week apart * Previously treated with a taxane and platinum-based regimen, only 1 prior platinum-based regimen, including IV or intraperitoneal consolidation, one additional non-platinum and non-topotecan chemotherapy regimen allowed * Life expectancy \>= 4 months * Total bilirubin =\< 1.5 times upper limit of normal (ULN) * AST =\< 2.5 times ULN (5 times ULN if liver metastases are present) * Creatinine =\< 1.5 times ULN AND creatinine clearance \> 40 mg/dL Exclusion criteria: * No presence of any other active cancer * No uncontrolled intercurrent illness, including the following: * Infection * Symptomatic congestive heart failure * Unstable angina pectoris * Cardiac arrhythmia * No history of severe allergy to platinum compounds * (Mild reaction (skin only) allowed provided a negative skin test is obtained) * No history of allergic reaction to appropriate antiemetics (e.g., 5HT3 antagonists) * Recovered from prior chemotherapy * At least 2 weeks since prior radiotherapy and recovered * At least 4 weeks since prior investigational drugs * No prior radiotherapy to the whole pelvic field * No unresolved sequelae resulting from any surgical procedures * No concurrent colony-stimulating factors (e.g., filgrastim \[G-CSF\] or sargramostim \[GM-CSF\]) during topotecan infusion * No concurrent participation in another investigational trial * No other concurrent investigational agents * No other concurrent anticancer therapy